Dankner’s takeover of ‘Ma’ariv’ approved

Deal is due to be closed within three weeks.

April 28, 2011 23:30
1 minute read.
Nochi Dankner

Nochi Dankner 58. (photo credit: Courtesy)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Antitrust Authority director- general David Gilo has approved the acquisition of the controlling interest in Ma’ariv Holdings Ltd. by Discount Investment Corporation, controlled by Nochi Dankner through IDB Holding Corp. Ltd. He ruled that the takeover of the owner of Hebrew daily Ma’ariv would not harm competition.

The deal is due to be closed within three weeks.
“A review of the merger by the Antitrust Authority found that it has horizontal, vertical and conglomerate aspects with other companies in the IDB group,” the Antitrust Authority said. “Among other things, we examined the effect of the merger on online and print publishing and competition between relevant business groups in markets where they operate. In view of the overall facts, we found that the merger does not raise concern about a significant harm to competition.”

Nevertheless, Gilo warned, “Any contract by Ma’ariv to provide or receive services from its competitor, or a person affiliated with it or a person who provides similar services to a competitor, is liable to result in restraint of trade that will require approval of the Antitrust Authority.”

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection


Cookie Settings